TARS
What one share of Tarsus Pharmaceuticals holds
Biological Products, (No Diagnostic Substances)
We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S.
Tarsus Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.12 |
|---|---|
| Profit | −$1.08 |
| Capex (buildings and equipment) | $0.42 |
| Free cash flow | $1.30 |
| Cash and investments | $10.39 |
| Debt | $1.68 |
| Book value | $8.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$1.98 | $0.07 | −$1.63 | $0.00 | −$2.27 |
| 2020 | $0.00 | −$4.32 | $0.07 | −$3.48 | $0.00 | — |
| 2021 | $2.77 | −$0.67 | $0.03 | $0.15 | $0.00 | $8.06 |
| 2022 | $1.05 | −$2.52 | $0.02 | −$2.01 | $0.00 | $7.22 |
| 2023 | $0.59 | −$4.62 | $0.05 | −$4.05 | $0.00 | $5.76 |
| 2024 | $4.87 | −$3.07 | $0.04 | −$2.25 | $0.00 | $5.85 |
| 2025 | $10.80 | −$1.59 | $0.24 | −$0.53 | $0.00 | $8.07 |